Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Apheresis and Dialysis"
DOI: 10.1111/1744-9987.13609
Abstract: Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat may be beneficial for patients who inadequately respond to erythropoiesis‐stimulating agents… read more here.
Keywords: eri; treatment; roxadustat darbepoetin; darbepoetin alfa ... See more keywords